Background: Procalcitonin (PCT) is a biomarker specific for bacterial infections versus viral or noninfectious causes. Utilizing PCT as a guide for antibiotic duration could have benefit in limiting antimicrobial overuse. Objective: The objective of this study was to analyze the effect of PCT monitoring on inpatient antibiotic duration for pneumonia and sepsis at a community hospital. Methods: This study utilized a prospective cohort design with a historical control group prior to the availability of PCT testing and a prospective intervention group after the availability of PCT testing at a community hospital. Results: A total of 102 patients (51 retrospective and 51 prospective) were included in the analysis. There was no difference in mean duration of inpatient antibiotics (6.1 ± 3.9 vs 5.4 ± 2.9 days, P = .50). Additionally, there was no difference in the average time to antibiotic de-escalation, average hospital length of stay, or intensive care unit length of stay. PCT monitoring resulted in a 41% reduction in discharge antibiotics (63% vs 37%, P = .0090) and a 2.2-day reduction in duration of overall inpatient and post-discharge antibiotics (9.5 ± 4.5 vs 7.3 ± 4.1 days, P = .013). There was no difference in mortality, relapse of infection, or 30-day readmission. Conclusion: PCT monitoring in patients with suspected pneumonia and/or sepsis in the community setting failed to show a reduction in duration of inpatient antibiotics after the introduction of PCT monitoring. However, PCT resulted in significantly fewer discharge antibiotics and overall inpatient plus post-discharge antibiotic duration, with no detrimental effect on mortality or readmission.
Background
Procalcitonin (PCT) is a biomarker released by C-cells of the thyroid gland as well as neuroendocrine cells of the lung and intestine as part of the inflammatory cascade. 1 PCT levels are only moderately increased in response to viral infections or noninfectious inflammatory states, making PCT a useful tool in identifying bacterial infections. 2 Current literature has demonstrated the benefit of using PCT in order to discontinue antibiotics in patients with sepsis and/or lower respiratory tract infections (LRTI). Within PCT algorithms, the most common PCT "threshold" for antibiotic discontinuation is 0.25 ng/mL for LRTI and 0.50 ng/mL for sepsis. 3 Serial levels of PCT concentrations can be trended, with decreases >80% warranting antibiotic discontinuation. 4 Single levels of PCT also have merit, with a negative predictive value ranging from 89% to 94% for LRTI and sepsis. 5, 6 Studies have shown a 1.5-to 4-day reduction in antibiotic duration when PCT algorithms were used to guide antibiotics in patients with sepsis and/or LRTI. [7] [8] [9] [10] Additionally, current literature suggests that PCT-guided antibiotic management is safe, with no associated increase in mortality or infection relapses. [7] [8] [9] [10] [11] [12] [13] [14] Nonetheless, adherence to PCT algorithms has been as low as 47% in current literature, suggesting the importance of providing systematic education when implementing PCT monitoring.
In addition to the clinical benefits of PCT monitoring, economic analyses suggest that decreases in antibiotic use outweigh the upfront costs of the test itself. PCT monitoring results in potential cost savings of 9.2% per patient, related to streamlining antibiotics and length of stay (LOS). 15 Of note, the cost savings through PCT monitoring are dependent on how frequently the test is ordered, along with costs avoided because of antibiotic discontinuation. 16 The clinical and economic benefits of PCT monitoring are reflected in current clinical guidelines. The 2016 Surviving Sepsis Guidelines acknowledge that PCT measurements can be utilized, along with other clinical evaluations, to guide antibiotic de-escalation in septic patients. 17 Similarly, the 2016 Infectious Diseases Society of America Guidelines for the Management of Adults with HospitalAcquired and Ventilator-Associated Pneumonia recommend using PCT levels plus clinical criteria to guide antibiotic discontinuation. 18 Despite the evidence in favor of PCT monitoring for antibiotic discontinuation, questions still surround the utility of PCT monitoring in clinical practice. Numerous trials have failed to show the benefit of PCT monitoring for the purposes of antibiotic initiation. 19, 20 Consequently, this study focuses on the use of PCT monitoring solely for antibiotic discontinuation/de-escalation. Current literature does not analyze the impact of PCT monitoring on duration of specific antimicrobials, which this study attempts to address. Additionally, current literature focuses solely on duration of inpatient antibiotics, while this study analyzes both inpatient and post-discharge antibiotics.
Prior to February 2017, PCT was available to order as a send-out lab and was rarely utilized at the institution. On February 1, 2017, PCT monitoring became available as an in-house test. A PCT algorithm was developed and distributed to providers prior to February 1, 2017 . The objectives of this study were to analyze the effect of PCT monitoring and algorithm on antibiotic duration for pneumonia and sepsis after the introduction of in-house PCT monitoring equipment at a community hospital.
Methods

Patients and Setting
This study was conducted at a 583-licensed bed, not-forprofit, acute care community hospital. Providers at the institution include hospitalists, intensivists, nurse practitioners, and medical residents. The hospital has had an active antimicrobial stewardship program since 2009, led by an infectious disease physician and pharmacist. The team reviews patients on antibiotics daily and makes recommendations to physicians when there are opportunities for improvement; however, the ASP had not yet utilized PCT as a stewardship tool prior to this study.
A prospective cohort study design with a historical control group was utilized. Patients were included in the control group if they had an ICD-10 (International Classification of Diseases, 10th Edition) code for sepsis and/or pneumonia prior to the implementation of in-house PCT testing (September to November 2016). Control patients were identified via retrospective report. Every 10th patient was selected for inclusion in the study, up to a total of 51 patients in the retrospective group.
Patients were included in the PCT group if they had ≥1 PCT level ordered after the availability of in-house testing during the month of February 2017 and a newly suspected infectious process of pneumonia and/or sepsis. Within the PCT group, patients were identified based on physician diagnosis in the patient chart. PCT patients were identified via E-mail alert from the MedMined Surveillance Advisor.
Patients were excluded from both groups of the study on the basis of the following conditions: pregnancy, age <19 years, severely immunocompromised patients (chemotherapy, radiation, or immunosuppressive therapy besides corticosteroids), severely neutropenic (<500 neutrophils/mL), chronic infections (endocarditis, osteomyelitis, mediastinitis postcardiac surgery), massive stress (burns ≥30% total body surface area, severe trauma), severe left heart failure (ejection fraction <30%), resuscitated cardiac arrest, continuous renal replacement therapy, and multiple sites of infection based on physician diagnoses (other than pneumonia + sepsis from any source). Institutional review board approval was obtained prior to study commencement and informed consent was waived.
Intervention
Nonbinding PCT algorithms ( Figure 1 ) were developed, approved by the infectious disease physician and Pharmacy and Therapeutics committee, and distributed to providers to provide guidance on interpreting PCT levels. The algorithm did not require physicians to order PCT, nor did it require them to accept recommendations based on PCT. PCT algorithms recommended use of PCT solely for antibiotic de-escalation or discontinuation, not initiation. For patients with both pneumonia and sepsis, providers were encouraged to utilize the more stringent LRTI threshold of 0.25 ng/mL.
Health care providers were educated about PCT testing via presentations at various hospital committee meetings (infection control, intensive care unit [ICU], sepsis), discussions with the family medicine residency program and hospitalists, and an electronic pamphlet. The algorithm criteria were viewable in the electronic medical record (EMR) when PCT levels resulted. Physicians ordered the initial PCT laboratory examinations as part of their normal patient care. A pharmacy resident and antimicrobial stewardship pharmacist actively followed PCT patients and made recommendations to providers if necessary. Recommendations were based on PCT results and clinical criteria in the form of notes written in the patient chart and/or phone calls to the provider. At the institution, pharmacists have medical staff approval to order subsequent PCT levels after a prescriber orders an initial level.
Study Data
Baseline demographics, temperature, white blood cell count, culture results, sepsis source, and antibiotics used were recorded. Time of PCT ordering in relation to the first dose of antibiotics was noted, and data were stratified by those with PCT ordered within 24 hours of antibiotic initiation versus those with PCT ordered ≥24 hours after antibiotic initiation. Data were analyzed by a prespecified subgroup of patients with pneumonia versus sepsis. PCT was measured using the VIDAS BRAHMS PCT assay (bioMerieux, Marcy-l'Étoile, France). The range of detection for the equipment is <0.05 ng/mL to >200 ng/mL.
Patients with a pneumonia diagnosis were assessed for clinical criteria of pneumonia, defined in study as new or progressing lung infiltrate on chest radiograph plus ≥2 of 3 Sepsis algorithm was identical, with the exception of a 0.5 ng/mL threshold to encourage antibiotic discontinuation, rather than 0.25 ng/mL as in the above algorithm.
clinical features: fever >100.4°F, leukocytosis, and purulent secretions. For the purposes of this study, hospital-acquired pneumonia (HAP) was defined as a pneumonia developing ≥48 hours after admission. Healthcare-associated pneumonia was defined as a pneumonia present on admission in a patient from a long-term care facility, hospitalization for ≥2 days in the last 90 days, chronic dialysis within 30 days, or antimicrobial therapy in the last 90 days. Communityacquired pneumonia was defined as pneumonia present on admission in a patient with no risk factors for multidrugresistant organism infection. Classification as HAP, healthcare-associated pneumonia, or community-acquired pneumonia was determined by the author's review of the above characteristics in the EMR.
The primary outcome was duration of inpatient antimicrobial therapy, defined as the number of days between the physician's start of antimicrobial therapy and the physician's discontinuation of antimicrobial therapy. Secondary outcomes included time to antibiotic de-escalation, which was defined as a change in the initially prescribed antibiotic regimen that resulted in the following: (1) reduction in number of antibiotics prescribed or (2) changing to a more narrow-spectrum regimen. Additional outcomes included LOS in the hospital and ICU, mortality, relapse of infection (defined as the reinitiation of antimicrobials for the initial infection within 72 hours after antimicrobials were stopped), 30-day all-cause readmission, and 30-day readmission because of infection. The percentage of patients discharged on antibiotics and total duration of inpatient plus post-discharge antibiotics were determined based on electronic discharge medication lists. Number of PCT stewardship recommendations accepted versus rejected was compared by reviewing pharmacists' clinical interventions documented in the EMR.
The total duration of each antibiotic in days was summed and multiplied by institution-specific cost per day to obtain total cost per antibiotic. The sum of all antibiotic costs yielded the "total antibiotic costs." For each patient in the study, antibiotic duration in days was multiplied by institution-specific cost per antibiotic per day. The results were summed and divided by number of patients to yield the "average antibiotic cost per patient."
Statistical Analysis
Statistical calculations were performed with SPSS Statistics Version 23 (IBM Corporation, Armonk, NY). Categorical data and proportions were analyzed via χ 2 test. The ShapiroWilk test was utilized to evaluate normality of data. Difference in duration of inpatient antimicrobial therapy was analyzed via Mann-Whitney U test. All other continuous data were evaluated via unpaired t test. A sample size of 102 patients (51 patients in both the retrospective and prospective groups) was required based on an assumed reduction in inpatient antibiotic duration of 2.5 days, with an expected standard deviation of 4.5 days to achieve 80% power and a confidence interval of 95%.
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Results
Fifty-one patients were enrolled in each of the retrospective and prospective groups for a total of 102 patients. Demographic data are presented in Table 1 . A total of 1046 patients were identified via retrospective report, with 51 patients included for analysis in the control group. For the PCT group, 87 patients had ≥1 PCT level drawn in the month of February 2017. Thirty-six patients were excluded from the prospective study, with the most common reason for exclusion being ejection fraction <30%. Differences in demographics between the 2 groups included a higher proportion of pneumonia diagnoses and diabetes mellitus in the PCT group and more positive microbiological culture results in the control group.
The median initial PCT value was 0.33 ng/mL (interquartile range = 0.075-1.48), drawn an average of 34.8 ± 40.6 hours after antibiotics were initiated. An average of 1.8 PCT levels was drawn per patient (range = 1-5 levels). A single PCT level was drawn in 25 patients. Distribution of initial PCT levels are shown in Table 1 . Six patients had a PCT level that decreased by >80% of the initial value. Forty-three patients qualified for antibiotic discontinuation because of the following: (1) initial PCT level below threshold, (2) decrease in PCT level below threshold, or (3) decrease by >80% of initial level. Among those eligible for discontinuation, 39 patients (91%) had antibiotics discontinued. Overall provider adherence to the algorithm was 80.4% (Supplement Table 1 , available in the online version of the article).
The average duration of antibiotics in the control group was 6.1 days compared with 5.4 in the PCT group (P = .50). The primary and secondary outcomes are presented in Table 2 . Of note, there was a 41% reduction in prescription of antibiotics at discharge. The overall inpatient plus postdischarge antibiotic duration was reduced by 2.2 days in the PCT group (9.5 vs 7.3, P = .013). In the subgroup analysis of patients with pneumonia, there was no difference in average inpatient antibiotic duration, but the average time to antibiotic de-escalation was 2.5 days lower in the PCT group (5.8 vs 3.3 days, P = .016). No difference was found when results were stratified by timing of PCT monitoring. There was no difference in duration among the top 5 antibiotics ordered in either group, with the exception of meropenem, which had a 2.1-day reduction in the PCT group (6.0 vs 3.9 days, P = .020; Table 3 ). Average antibiotic cost per patient did not differ between the 2 groups. There was no difference in mortality, infection relapse, 30-day all-cause readmission, or 30-day readmission because of infection between the 2 groups.
Discussion
This single-center, observational pre/post study failed to show a statistical reduction in duration of inpatient antibiotics in patients with pneumonia and/or sepsis at a community hospital after the introduction of PCT monitoring. However, significantly fewer patients were discharged on antibiotics after the availability of PCT monitoring. Additionally, the inpatient plus post-discharge antibiotic duration was shorter in the prospective group by 2.2 days. Reducing the number of patients discharged on antibiotics has potential implications in limiting adverse effects, overall antibiotic exposure, Clostridium difficile infections, health care costs, and antimicrobial resistance. The 0.7-day reduction in duration of inpatient antibiotics in the PCT group was smaller than expected based on previous prospective studies. [7] [8] [9] [10] [12] [13] [14] The ProREAL study found that the mean duration of antibiotic therapy in those with LRTI was 1.5 days shorter when a PCT algorithm was used to guide antibiotic decision-making compared with when a PCT algorithm was not followed (5.9 vs 7.4 days, P < .001). 7 Additional trials in critically ill and septic patients demonstrated a 2-to 3.5-day reduction in average antibiotic duration. [12] [13] [14] Of note, the duration of inpatient antibiotics in our control group (6.1 days) was shorter than expected based on the aforementioned literature (7.4-13.3 days), which could have blunted the effect size. [7] [8] [9] [10] 13 The low duration of antibiotics in the control group may have been Denotes significance of P < .05. The total duration of each antibiotic in days was summed manually and multiplied by institution-specific cost per day to obtain total cost per antibiotic (data not shown). The sum of all antibiotic costs yielded the "total antibiotic costs." For each patient in the study, antibiotic duration in days was multiplied by institution-specific cost per antibiotic per day. The results were summed and divided by number of patients to yield the "average antibiotic cost per patient." Table 2 . Primary and Secondary Outcomes.
Control Group (n = 51) Procalcitonin Group (n = 51) P Inpatient antibiotic duration, mean days (SD) 6.1 (± 3.9) 5.4 (± 2.9) .50 Time to antibiotic de-escalation, mean days (SD) 4.5 (± 2.9) 3.6 (± 1.9) .27 Antibiotics continued after patient discharge, n (%) 32 (63) 19 (37) .0090 Average inpatient + post-discharge antibiotic duration, mean days (SD) 9.5 (± 4.5) 7.3 (± 4.1) .013
Antibiotic clinical intervention made, n 8 28 <.0001 Antibiotic clinical intervention accepted, n (%) 7 (88) 24 (86) .88 LOS in hospital Mean days (SD) 7.9 (± 5.1) 9.7 (± 6.8) .13 Median days (IQR) 7 (5-9) 8 (6-12) LOS in ICU, mean days (SD) 3.9 (± 2.1) 5.0 (± 3.6) .17 Mortality, n (%) 4 (7.8) 1 (2) .18 Relapse in infection, n (%)
1 (2) 1 (2) 1.0 30-day readmission, n (%)
11 (22) 8 (16) .44 30-day readmission for infection, n (%)
10 (20) because of a below-average LOS during the retrospective time period, the lower proportion of pneumonia diagnoses, or the lower proportion of patients with comorbidities, such as diabetes mellitus. Furthermore, there were fewer patients with microbiological culture data in the PCT group versus control group, which may have contributed to longer empiric treatment durations in the PCT group. Additionally, we found that more patients in the retrospective group were discharged on antibiotics compared with the PCT group. Overall planned antibiotic duration (inpatient plus post-discharge) was reduced by as much as 2.2 days. Prior literature evaluating the effects of PCT on duration of antibiotics for sepsis and/or pneumonia has not distinguished between inpatient versus post-discharge antibiotics. However, our finding correlates with a study analyzing antimicrobial exposure in patients receiving usual care versus PCT monitoring and viral polymerase chain reaction testing. Patients with low PCT levels and positive viral test in the study were less likely to be discharged on antibiotics compared with those receiving usual care (20% vs 45%, P = .02). 21 Previous studies did not analyze duration of specific antimicrobials, but this study suggests that PCT monitoring may limit the use of broad-spectrum empiric antimicrobial therapy, such as meropenem. By reducing exposure to broad-spectrum antibiotics, PCT monitoring may assist in preserving the use of these antimicrobials for necessary infections.
Strengths of the present study include the use of PCT algorithms solely for de-escalation and discontinuation rather than the initiation of antimicrobials, in line with the Infectious Diseases Society of America HAP/VAP and Surviving Sepsis guidelines. 17, 18 Furthermore, this study included extensive provider education, as encouraged by prior literature. 22, 23 A wide variety of prescribers ordered initial PCT levels (hospitalists, intensivists, medical residents, etc) and provider compliance with our PCT algorithm was greater than 80%.
Education was particularly important regarding the interpretation of PCT levels in patients with conditions that can elevate PCT, such as renal failure. Though PCT undergoes minimal renal elimination, PCT levels may be elevated in patients with end-stage renal disease. 24 Nonetheless, analyzing PCT trends can still guide antibiotic therapy in this patient population, explaining why these patients were included in our study. The most common exclusion reason in our PCT group was ejection fraction <30%. Patients with severe left heart failure often have elevated PCT values. 25 Though we excluded such patients, PCT trends are likely valuable in this patient population, as well.
The present study does have several important limitations to note. First, the study was underpowered to detect the small effect size. Second, the study was not randomized and utilized a retrospective control. Thus, there may have been historical bias. Third, only 34 out of 102 patients in the overall study had a sepsis diagnosis, limiting our study's generalizability to patients with sepsis. Fourth, the study utilized different inclusion criteria in each of the groups to identify patients with pneumonia and/ or sepsis. In the retrospective group, ICD-10 codes were used because of feasibility, whereas, in the prospective group, inclusion was based on physician diagnosis in the patient chart. This decision was purposefully made, since PCT levels can provide antibiotic guidance for patients who may initially appear to have an infection (eg, pulmonary edema vs pneumonia on chest radiograph), who are ultimately deemed not to have an infection. The authors note that the different inclusion criteria could have introduced a confounding variable, but the decision was necessary because of feasibility within clinical practice.
Fifth, the prospective PCT study was performed in February 2017, immediately after the introduction of an inhouse PCT equipment when laboratory personnel were still undergoing equipment training and the lab often took >24 hours to result. This likely affected our primary outcome, and we predict that the reduction in antibiotic duration would likely have been greater if the PCT results were available in a timelier manner. Sixth, the antimicrobial stewardship team had a more prominent role in the PCT group than in the control group. Though the ASP team did contact providers and make antimicrobial recommendations in the control group, significantly more interventions were made in the PCT group, as expected. Last, our cost analysis focused solely on antimicrobial costs. Future analysis will be needed to determine the economic feasibility of PCT monitoring in the community hospital setting.
Conclusions
In summary, the introduction of PCT monitoring for patients with suspected pneumonia and/or sepsis demonstrated a nonsignificant difference of 0.7 days of inpatient antibiotics in the community hospital setting, but did result in significantly fewer discharge antibiotics and overall inpatient plus discharge antibiotics. Additionally, our study suggests that PCT monitoring may be a useful tool in decreasing duration of empiric broad-spectrum antibiotics, such as meropenem, with no detrimental effects on mortality, infection relapses, or 30-day readmissions.
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